KZR - Kezar Life Sciences, Inc.

QQQ $ 618.35 $ -12.83 (-2.03 %)

DIA $ 471.55 $ -2.57 (-0.54 %)

SPY $ 675.36 $ -8.10 (-1.19 %)

TLT $ 89.94 $ 0.20 (0.22 %)

GLD $ 361.65 $ -6.46 (-1.75 %)

Previous Close

$ 6.09

Open

$ 6.06

Bid

$ 6.00 x 3

Ask

$ 6.09 x 700

Day's Range

$ 6.05 - $ 6.14

52 Week Range

$ 3.53 - $ 7.65

Volume

41,341

Average Volume

Market Cap

44.89M

Beta (5Y Monthly)

$ 1.04

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-13-2025	06-30-2025	10-Q
2	05-13-2025	03-31-2025	10-Q
3	03-25-2025	12-31-2024	10-K
4	11-12-2024	09-30-2024	10-Q
5	08-13-2024	06-30-2024	10-Q
6	05-09-2024	03-31-2024	10-Q
7	03-14-2024	12-31-2023	10-K
8	11-13-2023	09-30-2023	10-Q
9	08-10-2023	06-30-2023	10-Q
10	05-11-2023	03-31-2023	10-Q
11	03-14-2023	12-31-2022	10-K
12	11-10-2022	09-30-2022	10-Q
13	08-11-2022	06-30-2022	10-Q
14	05-12-2022	03-31-2022	10-Q
15	03-17-2022	12-31-2021	10-K
16	11-09-2021	09-30-2021	10-Q
17	08-12-2021	06-30-2021	10-Q
18	05-12-2021	03-31-2021	10-Q
19	03-11-2021	12-31-2020	10-K
20	11-05-2020	09-30-2020	10-Q
21	08-06-2020	06-30-2020	10-Q
22	05-07-2020	03-31-2020	10-Q
23	03-12-2020	12-31-2019	10-K
24	11-07-2019	09-30-2019	10-Q
25	08-07-2019	06-30-2019	10-Q
26	05-07-2019	03-31-2019	10-Q
27	03-26-2019	12-31-2018	10-K
28	11-08-2018	09-30-2018	10-Q
29	08-09-2018	06-30-2018	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Jefferies Downgrades Kezar Life Sciences t...
10/17/2025 19:08:03

Jefferies analyst Maury Raycroft downgrades Kezar Life Sciences (NASDAQ:KZR) from Buy to Hold and lowers the price target fr...

kezar-launches-strategic-review-as-fda-roadblock-derails-liver-drug-plans

Kezar Launches Strategic Review As FDA Roa...
10/17/2025 18:38:05

Kezar Life Sciences faces FDA delays for AIH drug trials, implements restructuring, and explores strategic alternatives amid po...

12 Health Care Stocks Moving In Friday's I...
10/17/2025 17:05:58

this-booz-allen-hamilton-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday

This Booz Allen Hamilton Analyst Is No Lon...
10/17/2025 16:23:02

William Blair Downgrades Kezar Life Scienc...
10/17/2025 14:22:55

William Blair analyst Matt Phipps downgrades Kezar Life Sciences (NASDAQ:KZR) from Outperform to Market Perform.

Wells Fargo Maintains Equal-Weight on Keza...
10/17/2025 13:01:02

Wells Fargo analyst Derek Archila maintains Kezar Life Sciences (NASDAQ:KZR) with a Equal-Weight and lowers the price target...

12 Health Care Stocks Moving In Friday's P...
10/17/2025 12:13:10

why-csx-shares-are-trading-higher-by-over-4-here-are-20-stocks-moving-premarket

Why CSX Shares Are Trading Higher By Over ...
10/17/2025 09:55:54

12 Health Care Stocks Moving In Thursday's...
10/16/2025 21:06:04

Kezar Life Sciences Initiates Strategic Al...
10/16/2025 20:09:33

Kezar Life Sciences, Inc. (NASDAQ:KZR, the Company))), a clinical-stage biotechnology company developing novel small molecule t...

Kezar Life Sciences Q2 EPS $(1.87) Beats $...
08/13/2025 20:04:50

fda-lifts-pause-on-kezars-liver-drug-trialnext-stop-lupus-study

FDA Lifts Pause On Kezar's Liver Drug Tria...
07/16/2025 15:54:15

Kezar Life Sciences' zetomipzomib trial in autoimmune hepatitis resumes as FDA lifts partial hold following a favorable saf...

HC Wainwright & Co. Reiterates Neutral on ...
07/16/2025 11:28:00

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) from Neutral to Neutral.

Kezar Life Sciences Plans To Request FDA L...
07/15/2025 20:43:06

Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Inde...

Kezar Life Sciences Announces FDA Lifted P...
07/15/2025 20:41:54

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to ...

Kezar Life Sciences Q1 EPS $(2.27) Beats $...
05/14/2025 05:37:56

Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate of $(...

kezar-life-sciences-touts-positive-data-from-mid-stage-study-for-chronic-liver-disease-drug-candidate

Kezar Life Sciences Touts Positive Data Fr...
03/25/2025 14:39:45

Kezar Life Sciences reports positive Phase 2a data for zetomipzomib in autoimmune hepatitis, showing higher response rates and ...

Kezar Life Sciences Q4 2024 GAAP EPS $(2.7...
03/25/2025 11:55:03

Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(2.77) per share which beat the analyst consensus estimate of $(...

Kezar Life Sciences Provides Topline Resul...
03/25/2025 11:52:55

Company-hosted conference call and webcast to be held today at 8:00 a.m. ETZetomipzomib treatment results in steroid-sparing bi...

Kezar Life Sciences To Present Topline Res...
03/24/2025 12:14:55